taurine has been researched along with Muscular Dystrophy, Duchenne in 15 studies
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A milder form of the disease, Becker muscular dystrophy (BMD), is characterised by the presence of a semi-functional truncated dystrophin, or the full-length dystrophin at reduced level." | 2.43 | [Pharmacological treatments for Duchenne and Becker dystrophies]. ( de la Porte, S; Voisin, V, 2005) |
| "Taurine is an amino acid abundantly present in heart and skeletal muscle." | 1.51 | A long-term treatment with taurine prevents cardiac dysfunction in mdx mice. ( Bove, M; Camerino, GM; Capogrosso, RF; Conte, E; De Bellis, M; De Luca, A; Mantuano, P; Mele, A; Morgese, MG; Pierno, S; Rana, F; Rolland, JF; Sanarica, F; Trabace, L, 2019) |
| "Taurine treatment of mdx mice only altered ncRNA levels when administered from 18 days to 6 weeks of age, but a deficiency in tRNA levels was rectified earlier in mdx skeletal muscles treated from 14 days to 3 weeks." | 1.48 | Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment. ( Butchart, LC; Filipovska, A; Grounds, MD; Rossetti, G; Terrill, JR; White, R, 2018) |
| "Taurine treatment also reduced protein thiol oxidation and was overall more effective, as OTC treatment reduced body and muscle weight, suggesting some adverse effects of this drug." | 1.43 | Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy. ( Arthur, PG; Graves, JA; Grounds, MD; Pinniger, GJ; Terrill, JR, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merckx, C | 1 |
| Cosemans, G | 1 |
| Zschüntzsch, J | 1 |
| Raedt, R | 1 |
| Schmidt, J | 1 |
| De Paepe, B | 1 |
| De Bleecker, JL | 1 |
| Ren, X | 1 |
| Xu, H | 3 |
| Barker, RG | 3 |
| Lamb, GD | 1 |
| Murphy, RM | 3 |
| Terrill, JR | 5 |
| Webb, SM | 1 |
| Arthur, PG | 4 |
| Hackett, MJ | 1 |
| Wyckelsma, VL | 1 |
| Frankish, BP | 1 |
| Butchart, LC | 1 |
| Rossetti, G | 1 |
| White, R | 1 |
| Filipovska, A | 1 |
| Grounds, MD | 4 |
| Mele, A | 1 |
| Mantuano, P | 2 |
| De Bellis, M | 2 |
| Rana, F | 1 |
| Sanarica, F | 1 |
| Conte, E | 1 |
| Morgese, MG | 1 |
| Bove, M | 1 |
| Rolland, JF | 2 |
| Capogrosso, RF | 3 |
| Pierno, S | 2 |
| Camerino, GM | 2 |
| Trabace, L | 1 |
| De Luca, A | 4 |
| Boyatzis, A | 1 |
| Pinniger, GJ | 1 |
| Graves, JA | 1 |
| Cozzoli, A | 2 |
| Massari, AM | 1 |
| Sblendorio, VT | 2 |
| Tamma, R | 1 |
| Giustino, A | 1 |
| Nico, B | 2 |
| Montagnani, M | 1 |
| Longo, V | 1 |
| Simonetti, S | 1 |
| Liantonio, A | 1 |
| Conte Camerino, D | 1 |
| Voisin, V | 1 |
| de la Porte, S | 1 |
| Gulston, MK | 1 |
| Rubtsov, DV | 1 |
| Atherton, HJ | 1 |
| Clarke, K | 1 |
| Davies, KE | 1 |
| Lilley, KS | 1 |
| Griffin, JL | 1 |
2 reviews available for taurine and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness.
Topics: Adrenal Cortex Hormones; Animals; Chloride Channels; Disease Progression; Dystrophin; Humans; Insuli | 2002 |
[Pharmacological treatments for Duchenne and Becker dystrophies].
Topics: Adrenal Cortex Hormones; Adult; Aminoglycosides; Animals; Carnitine; Child; Child, Preschool; Creati | 2005 |
13 other studies available for taurine and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
Description of Osmolyte Pathways in Maturing
Topics: Animals; Inositol; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, | 2022 |
Elevated MMP2 abundance and activity in mdx mice are alleviated by prenatal taurine supplementation.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Female; Male; Matrix Metalloproteinase 2; Matr | 2020 |
Investigation of the effect of taurine supplementation on muscle taurine content in the mdx mouse model of Duchenne muscular dystrophy using chemically specific synchrotron imaging.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Mu | 2020 |
Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
Topics: Animals; Citrate (si)-Synthase; Dietary Supplements; Disease Models, Animal; Disease Progression; El | 2018 |
Elevated GLUT4 and glycogenin protein abundance correspond to increased glycogen content in the soleus muscle of mdx mice with no benefit associated with taurine supplementation.
Topics: Animals; Glucose Transporter Type 4; Glucosyltransferases; Glycogen; Glycoproteins; Male; Mice; Mice | 2018 |
Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; | 2018 |
A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
Topics: Animals; Drinking; Hindlimb; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Contraction; M | 2019 |
Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
Topics: Acetylcysteine; Animals; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Muscular Dystrophy, | 2013 |
Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
Topics: Animals; Biological Transport; Chromatography, High Pressure Liquid; Cysteine; Disease Models, Anima | 2015 |
Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Topics: Animals; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Co | 2016 |
Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
Topics: Acetophenones; Animals; Antioxidants; Disease Models, Animal; Male; Methylprednisolone; Mice; Mice, | 2016 |
Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Chromatography, High Pressure Liquid; Creatine Kinase; Disease Models, Animal; Drug Synergi | 2011 |
A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart.
Topics: Aging; Animals; Dystrophin; Male; Metabolism; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular D | 2008 |